BioStem Technologies (BSEM)
OTHER OTC:BSEM
Earnings Data
Report Date
May 18, 2026During Market Hours (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.17Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced: the call communicated meaningful strategic positives — a transformational acquisition expanding addressable markets, strong clinical data (DFU RCT), product and commercial expansion, and a clear path to materially higher manufacturing margins after tech transfer. However, these longer-term strengths are offset by significant near-term financial headwinds: steep year-over-year revenue declines, a sizable one-time $8.8M allowance tied to distributor collections, higher operating expenses, lower blended margins during a 12-month contract manufacturing period, reduced post-close cash (~$16M) and expected cash consumption through much of 2026. Management has articulated a credible integration and commercialization plan, but near-term liquidity and execution risks temper the outlook.Company Guidance
Strategic Acquisition of BioTissue Assets
Closed acquisition of BioTissue surgical and wound assets (closed Jan 21, 2026) that expands BioStem into hospital inpatient, HOPD and ASC settings, diversifies payer mix and adds ~ $29M of 2025 revenue from the acquired assets (per management).
Clinically Differentiated Trial Results (DFU)
Published top-line results from the DFU randomized controlled trial showing statistically significant superiority of BioREtain-processed allografts versus standard of care; VLU top-line results expected mid-2026. Management expects clinical data to drive hospital adoption and payer coverage.
Fourth Quarter Gross Margin Expansion
Q4 2025 gross profit of $9.8M and gross margin of 97% versus $9.3M and 88% in the prior period (up 9 percentage points). Margin expansion driven by product mix shift toward items without licensing fees.
Product Portfolio and Technology Stack Expansion
Addition of Neox and Clarix product families plus CryoTek and SteriTek platforms alongside BioREtain; more than 25 years of clinical experience across the acquired portfolio and >1M patients historically treated with the technology.
Immediate Commercial Footprint Expansion
Acquired an experienced national sales footprint (>25 direct reps and >30 independent agents) and reassigned major GPO contracts to access hospital, outpatient and ASC customers; plan to ramp to at least 40 direct reps to broaden geographic penetration.
Manufacturing Margin Upside Opportunity
Temporary outsourced manufacturing yields ~60% gross margin on acquired products (includes 23% cost-plus markup). Management expects to complete tech transfer within ~12 months and to capture materially higher in‑house margins (targeting >80%+ for those products).
Audit Progress and Corporate Governance
Appointed KPMG in Oct 2025 and expects to finalize 2024 & 2025 audits soon as a step toward a planned NASDAQ uplisting; also announced appointment of Jodi Ungrodt as Audit Committee Chair to strengthen governance.
Product & Commercial Milestones Planned for 2026
Plan to launch BioREtain preserved dry products to hospital customers in Q2 2026 and expect a new medical device launch pending FDA 510(k) clearance (milestone payment timing tied to this clearance).
BSEM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BSEM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 24, 2026 | $5.12 | $4.92 | -3.91% |
Nov 13, 2025 | $4.14 | $3.98 | -3.99% |
Aug 14, 2025 | $10.38 | $7.04 | -32.14% |
May 12, 2025 | $15.20 | $12.63 | -16.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioStem Technologies (BSEM) report earnings?
BioStem Technologies (BSEM) is schdueled to report earning on May 18, 2026, During Market Hours (Confirmed).
What is BioStem Technologies (BSEM) earnings time?
BioStem Technologies (BSEM) earnings time is at May 18, 2026, During Market Hours (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSEM EPS forecast?
Currently, no data Available